FDA approves generic blood thinner

July 26, 2010 By Andrew Zajac

In a closely watched decision, the Food and Drug Administration on Friday approved an application by German drug-maker Sandoz and Momenta Pharmaceuticals of Cambridge, Mass, to make the first generic version of the widely used blood thinner Lovenox.

The approval positions Momenta and Sandoz to offer a cheaper but still lucrative alternative to Lovenox, which had sales of $4.5 billion in 2009, making it the 15th best selling drug in the world.

In its decision, the FDA also rejected an argument by Lovenox's maker, Sanofi-Avenis, that its drug, which is made from found in heparin, a substance derived from pig intestines, is too complex to be copied with precision by makers of generic versions of the medication.

The Sandoz/Momenta team had been in a bitter, five-year battle with Amphastar Pharmaceuticals, of Rancho Cucamonga, Calif., to win the FDA's nod to make the drug, which goes by the generic name enoxaparin.

Amphastar last year accused Janet Woodcock, the FDA's top drug official, of a conflict of interest involving her past associations with Momenta scientists. The complaint was dismissed by the Department of Health and Human Services Inspector General.

"The approval of M-enoxaparin marks a key milestone for Momenta and we are extremely pleased," Momenta CEO Craig Wheeler said in a statement.

Shares of Momenta, which supplied the technology in its partnership, zoomed to $21.70, up $9.77, an increase of more than 80 percent. Shares of Sandoz' parent, Swiss pharma conglomerate Novartis, closed down 35 cents at $49.21.

Sanofi shares lost $1.29, closing at $29.35.

The contours of the FDA announcement could bode well for Momenta, according to analyst Bret Holley, of Oppenheimer Co.

The Momenta's partnership agreement with Sandoz is much more generous if their application is the only one approved, Holley said.

Typically, Holley said, when the FDA rejects a petition by a drug's original maker as it did with Sanofi Avenis, it announces all the generic approvals at the same time, suggesting that Sandoz/Momenta might be the only application slated for approval.

Holley also said that the painstaking review of the Sanofi Avenis request, conveyed in a 45-page letter, suggests that the FDA will move cautiously when considering generic versions of drugs derived from natural substances.

"I don't believe that they're going to be approving applications (for biogenerics) willy-nilly," he said.

Amphastar attorney Jason Shandell declined to specify his company's next move, but hinted that it was not ready to throw in the towel.

"As the first filer, we're obviously very disappointed and we will do everything we can to allow the system to correct such a mistake," Shandell said. Amphastar applied to make enoxaparin in 2003, two years earlier than Sandoz/Momenta.

The FDA still could approve Amphastar's application, but the company would not have first-mover advantage and would be competing against the global distribution capabilities of Sandoz.

Amphastar's allegation of a involving Woodcock centered on her partnering with Momenta scientists in investigating the crisis in early 2008 in which contaminated lots of the drug from China sickened, and in some cases killed, patients.

Amphastar argued that the collaboration and earlier contacts between Woodcock and Momenta scientists inclined the FDA to favor Momenta.

Momenta has said that there is nothing inappropriate in its relationship with regulators.

Related Stories

Recommended for you

Glucocorticoids offer long-term benefits for patients with Duchenne muscular dystrophy

November 22, 2017
Glucocorticoids, a class of steroid hormone medications often prescribed to patients with Duchenne muscular dystrophy (DMD), offer long-term benefits for this disease, including longer preservation of muscle strength and ...

Baby-boomers and millennials more afflicted by the opioid epidemic

November 21, 2017
Baby-boomers, those born between 1947 and 1964, experienced an excess risk of prescription opioid overdose death and heroin overdose death, according to latest research at Columbia University's Mailman School of Public Health. ...

Sensor-equipped pill raises technological, ethical questions

November 17, 2017
The first drug with a sensor embedded in a pill that alerts doctors when patients have taken their medications was approved by the Food and Drug Administration, raiding issues involving privacy, cost, and whether patients ...

New painkillers reduce overdose risk

November 16, 2017
Scientists on the Florida campus of The Scripps Research Institute (TSRI) have developed new opioid pain relievers that reduce pain on par with morphine but do not slow or stop breathing—the cause of opiate overdose.

Separating side effects could hold key for safer opioids

November 16, 2017
Opioid pain relievers can be extremely effective in relieving pain, but can carry a high risk of addiction and ultimately overdose when breathing is suppressed and stops. Scientists have discovered a way to separate these ...

US regulators approve first digital pill to track patients

November 14, 2017
U.S. regulators have approved the first drug with a sensor that alerts doctors when the medication has been taken, offering a new way of monitoring patients but also raising privacy concerns.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.